TerminatedPhase 1, PHASE2

GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

Lead sponsor

CellMed AG, a subsidiary of BTG plc.

Asset

GLP-1 CellBeads

Listed sites

Recruiting sites

Actual enrollment

Study population

Cardiovascular disease

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01298830

Org study IDCM GLP-1/01

Secondary ID2007-004516-31

Timeline

Milestones

Study first posted2011-02-18estimated

Last update posted2013-03-26estimated

Study start2008-10 (month precision)

Primary completion2011-06actual (month precision)

Study completion2011-06actual (month precision)

Assets

Investigational agents

GLP-1 CellBeads

Who this study enrolls

Cardiovascular disease

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Confirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance Tomography (MRT)

•Patients who need by judgement of a clinical neurologist or neurosurgeon surgical removal of the blood clot due to its space-occupying effects

•Age greater or equal 18 years for men

•Age greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or surgical sterilisation at least 3 months before study start)

•For all other women age greater or equal 50 years with last menstrual bleeding at least one year before study start

•Minimum hematoma diameter of 2 cm as measured in baseline CCT or MRT

•Signed, written informed consent of patient or consent/assertion from the patient's legally acceptable representative/affiliated if the patient is unable to provide informed consent

Exclusion criteria

•Participation in any other clinical trial within the past 3 months or ongoing

•Occurrence of inconsistency with initial diagnosis at baseline during surgery of the patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or trauma

•Patients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into the brainstem

•Patients with severe pre-existing physical or mental disability or severe comorbidity that interferes with the assessment of outcome

•Allergy to contrast media (MRT)

•Acute infection

•Muscular, neurological, or vascular insufficiency of the respective tissue

•Polypropylene incompatibility

•Acute immunosuppressive medication

•Patient after organ transplantation

•Patient with immune depression

•Patients with a high probability of spontaneous recovery or showing rapidly improving signs

•Patients with extensive intracranial hemorrhages or with deep hemispheric localisation of the clots

•Patients whose diagnosis of ICH is uncertain

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.